Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun 30;5(7):e607.
doi: 10.1097/HS9.0000000000000607. eCollection 2021 Jul.

The EHA Research Roadmap: Anemias

Affiliations
Editorial

The EHA Research Roadmap: Anemias

Achille Iolascon et al. Hemasphere. .

Erratum in

No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Graphical representations of the aims of the Research Roadmap for Anemias in Europe during the period 2020–2025.
Figure 2.
Figure 2.
Schematic representation of pathogenic mechanism of DHS and new discovery on Plasmodium infection. (A) Recent study demonstrated that RBCs of DHS patients with PIEZO1 gain-of-function (GOF) mutations show a low rate of infection by Plasmodium falciparum. (B) RBCs of DHS patients show dehydration that is caused by the increased potassium efflux and increased calcium influx of PIEZO1 GoF mutations or KCNN4/Gardos GoF mutations. Senicapoc, a Gardos antagonist, is able to restore the hydration status in both PIEZO1 and KCNN4 mutants. (C) RBCs of DHS patients with GoF mutations in PIEZO1 show delayed terminal differentiation and reticulocytes maturation. (D) At the hepatic level, PIEZO1 GoF mutations in DHS result in increased intracellular Ca2+ concentrations. The hyperactivation of the mechanoreceptor leads to amplification of the phosphorylation of ERK1/2, which acts in turn by inhibiting the BMP/SMADs pathway. The lack of phosphorylation of SMAD1/5/8 inactivates HAMP transcription.
Figure 3.
Figure 3.
Standard and target therapies for warm autoimmune hemolytic anemia (wAIHA) and cold agglutinin disease (CAD). The figure shows the several immunologic mechanisms involved in pathogenesis, including macrophages, T and B lymphocytes, cytokines, activation of the complement cascade, antibody-dependent cellular cytotoxicity (ADCC) in the spleen and/or complement-dependent cytotoxicity (CDC) in the liver, and possible inadequate bone marrow compensation. Standard therapies include steroids and immunosuppressors that act not specifically on the various mechanisms, and splenectomy. Target therapies are directed against specific immunological mechanisms either inhibiting the immune attack or stimulating bone marrow compensation. APC = antigen presenting cell; BAFF = B-cell activating factor; BM = bone marrow; BTK = Bruton tyrosine kinase; CAD = cold agglutinin disease; EPO = erythropoietin; FcRn = neonatal Fc receptor; MMF = mycophenolate mofetil; PI3K = phosphoinositide 3-kinase; Syk = spleen tyrosine kinase.

References

    1. Engert A, Balduini C, Brand A, et al. . The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica. 2016; 101:115–208 - PMC - PubMed
    1. de Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of anaemia 1993-2005. In: WHO Global Database on Anaemia. Geneva, Switzerland: World Health Organization, 2008; 1–35
    1. Andro M, Le Squere P, Estivin S, et al. . Anaemia and cognitive performances in the elderly: a systematic review. Eur J Neurol. 2013; 20:1234–1240 - PubMed
    1. Abel GJ, Sander N. Quantifying global international migration flows. Science. 2014; 343:1520–1522 - PubMed
    1. Buermans HP, den Dunnen JT. Next generation sequencing technology: advances and applications. Biochim Biophys Acta. 2014; 1842:1932–1941 - PubMed

Publication types